DarioHealth Q3 2023 Earnings Report

DarioHealth EPS Results

• Actual EPS: -$0.49
• Consensus EPS: -$0.50
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

DarioHealth Revenue Results

• Actual Revenue: $3.52 million
• Expected Revenue: $4.13 million
• Beat/Miss: Missed by -$610.00 thousand
• YoY Revenue Growth: N/A

DarioHealth Announcement Details

• Quarter: Q3 2023
• Date: 11/2/2023
• Time: N/A

DarioHealth (NASDAQ:DRIO) operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.